TY - JOUR
T1 - Variation in care in concurrent chemotherapy administration during radiation for locally advanced cervical cancer
AU - Uppal, Shitanshu
AU - del Carmen, Marcela G.
AU - Rice, Laurel W.
AU - Reynolds, R. Kevin
AU - Jolly, Shruti
AU - Bregar, Amy
AU - Abdelsattar, Zaid M.
AU - Rauh-Hain, J. Alejandro
N1 - Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background To evaluate the usage of concurrent chemo-radiotherapy (C-CRT) for the treatment of locally advanced cervical cancer. Methods Patients with locally invasive cervical carcinoma diagnosed between January 1, 2004 and December 31, 2012 from the National Cancer Database (NCDB) were included. Outcomes for patients undergoing radiation therapy only, ‘RT alone’ group were compared to those receiving chemotherapy concurrent with radiation ‘C-CRT group’. Trends in utilization of C-CRT and factors associated with the deviation from standard of care were explored. Lastly, the effect of hospital volume on utilization of C-CRT was investigated. Results A total of 18,164 patients undergoing definitive radiation therapy were available for analysis. Utilization of C-CRT increased from 72.4% in 2004 to 84.3% in 2012 (p-trend < 0.001). After adjusting for patient, tumor, and treatment factors, a multivariable logistic regression model revealed increasing age, African-American race, Charlson-comorbidity index of ≥ 2, Medicaid insurance status, uninsured status, and Stage I disease were each independently associated with the lack of C-CRT. After adjusting for patient characteristics, low volume hospitals were noted to have overall significantly lower rates and greater variation in C-CRT administration. Patients in ‘RT alone’ group had an overall worse survival rate (adjusted-HR 1.47, 95%CI 1.4–1.56). Conclusion Rates of C-CRT administration varied significantly across hospitals in the United States. Hospitals with a high case volume had higher rates and more consistent patterns of C-CRT administration. Furthermore, we identified independent factors, all of which represent noteworthy health disparities, associated with lower rates of C-CRT administration.
AB - Background To evaluate the usage of concurrent chemo-radiotherapy (C-CRT) for the treatment of locally advanced cervical cancer. Methods Patients with locally invasive cervical carcinoma diagnosed between January 1, 2004 and December 31, 2012 from the National Cancer Database (NCDB) were included. Outcomes for patients undergoing radiation therapy only, ‘RT alone’ group were compared to those receiving chemotherapy concurrent with radiation ‘C-CRT group’. Trends in utilization of C-CRT and factors associated with the deviation from standard of care were explored. Lastly, the effect of hospital volume on utilization of C-CRT was investigated. Results A total of 18,164 patients undergoing definitive radiation therapy were available for analysis. Utilization of C-CRT increased from 72.4% in 2004 to 84.3% in 2012 (p-trend < 0.001). After adjusting for patient, tumor, and treatment factors, a multivariable logistic regression model revealed increasing age, African-American race, Charlson-comorbidity index of ≥ 2, Medicaid insurance status, uninsured status, and Stage I disease were each independently associated with the lack of C-CRT. After adjusting for patient characteristics, low volume hospitals were noted to have overall significantly lower rates and greater variation in C-CRT administration. Patients in ‘RT alone’ group had an overall worse survival rate (adjusted-HR 1.47, 95%CI 1.4–1.56). Conclusion Rates of C-CRT administration varied significantly across hospitals in the United States. Hospitals with a high case volume had higher rates and more consistent patterns of C-CRT administration. Furthermore, we identified independent factors, all of which represent noteworthy health disparities, associated with lower rates of C-CRT administration.
KW - Cervix cancer
KW - Concurrent chemo radiation
KW - Health disparities
KW - Variation in care
UR - http://www.scopus.com/inward/record.url?scp=84970003191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84970003191&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.05.026
DO - 10.1016/j.ygyno.2016.05.026
M3 - Article
C2 - 27234144
AN - SCOPUS:84970003191
SN - 0090-8258
VL - 142
SP - 286
EP - 292
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -